30 closest matches · ranked by relevance
Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome · Myelodysplastic Syndrome
Primary: Failure-free Survival (Failure Defined as Death or Relapse) — 6; 10 Participants
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Complete Response Rate — 35.3 percentage of participants
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Leukemia
Primary: Percentage of Participants With Relapse-free Survival (RFS) — 52 percentage of participants
Myelodysplastic Syndrome
Primary: Number of Participants With Response — 2; 2; 4; 6 participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Overall Survival — 25 Participants
Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Overall Survial Time — 18.3 months
Acute Myeloid Leukemia · Myeloid and Monocytic Leukemia · Myelodysplastic Syndromes
Primary: Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS) — 36 Percentage of…
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia
Primary: Progression-free Survival — 41.2; 26.9 percentage of patients
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria — 14; 8; 1; 7 Participants
Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasms
Primary: Number of Participants With Response — 0; 0; 3; 1 participants
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Myelodysplastic Syndromes
Primary: Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities as Measured by NCI CTC v2.0 — 5; 14; 7; 28 Participants
Leukemia · Myelodysplastic Syndromes
Primary: Complete and Partial Remission Per the International Working Group (IWG) Criteria for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) — 30; 25; 10…
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Number of Confirmed Responses (Complete Response, Partial Response, or Hematologic Improvement) Noted on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1; 0; 0…
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Acute Myeloid Leukemia/Transient Myeloproliferative Disorder · Adult Acute Myeloid Leukemia in Remission
Primary: Overall Survival — 6; 6 participants
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
Myelodysplastic Syndrome
Primary: Participants Survival Status as of the Time of the Extension Study Follow-up — 101; 29; 18 participants
Myelodysplastic Syndromes
Primary: Overall Response Rate Based on the Modified International Working Group (IWG) 2006 Response Criteria for Myelodysplastic Syndrome (MDS) — 6.3; 4.5; 16.7; 0 Percentage of…
Myelodysplastic Syndromes (MDS) · Acute Myelogenous Leukemia (AML)
Primary: Relapse Rate — 20; 2; 10 Participants
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome
Primary: Number of Patients With HCT Failure. — 4; 0; 0; 5 Participants
Leukemia
Primary: Overall Response Rate (ORR) — 0; 3 Participants
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) — 3; 20; 23 Participants — p=<0.001
Myelodysplastic Syndromes
Primary: Number of Participants Who Experienced an Adverse Event — 6 participants
Leukemia, Erythroblastic, Acute · Myelodysplastic Syndromes
Primary: Disease Free Survival at 1 Year Post-transplant — 18 Participants